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RESEARCH ARTICLE Open Access
Vascular disrupting agent for neovascular age
related macular degeneration: a pilot study of the
safety and efficacy of intravenous combretastatin
a-4 phosphate
Mohamed A Ibrahim1, Diana V Do1,6, Yasir J Sepah1, Syed M Shah1, Elizabeth Van Anden1, Gulnar Hafiz1,
J Kevin Donahue2,3, Richard Rivers4, Jai Balkissoon5, James T Handa1, Peter A Campochiaro1
and Quan Dong Nguyen1,6*
Abstract
Background: This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P
in patients with neovascular age-related macular degeneration (AMD).
Methods: Prospective, interventional, dose-escalation clinical trial. Eight patients with neovascular AMD refractory to
at least 2 sessions of photodynamic therapy received CA4P at a dose of 27 or 36 mg/m2 as weekly intravenous
infusion for 4 consecutive weeks. Safety was monitored by vital signs, ocular and physical examinations,
electrocardiogram, routine laboratory tests, and collection of adverse events. Efficacy was assessed using retinal
fluorescein angiography, optical coherence tomography, and best corrected visual acuity (BCVA).
Results: The most common adverse events were elevated blood pressure (46.7%), QTc prolongation (23.3%),
elevated temperature (13.3%), and headache (10%), followed by nausea and eye injection (6.7%). There were no
adverse events that were considered severe in intensity and none resulted in discontinuation of treatment. There
was reduction of the excess foveal thickness by 24.15% at end of treatment period and by 43.75% at end of the
two-month follow-up (p = 0.674 and 0.161, respectively). BCVA remained stable throughout the treatment and
follow-up periods.
Conclusions: The safety profile of intravenous CA4P was consistent with that reported in oncology trials of CA4P
and with the class effects of vascular disruptive agents; however, the frequency of adverse events was different.
There are evidences to suggest potential efficacy of CA4P in neovascular AMD. However, the level of systemic
safety and efficacy indicates that systemic CA4P may not be suitable as an alternative monotherapy to current
standard-of-care therapy.
Trial registration: ClinicalTrials.gov NCT01570790.
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Background
Combretastatin-A4-phosphate (CA4P) is a vascular disrup-
ting agent (VDA), a class of experimental medications that
lead to collapse or occlusion of abnormal vascular struc-
tures. CA4P is a synthetic phosphorylated pro-drug of
CA4, a naturally occurring derivative of the South African
willow tree, combretum caffrum, which reversibly binds
tubulin at the colchicine-binding site to inhibit microtubule
assembly. The mechanism by which CA4P and CA4 act on
pathologic neovasculature is not completely understood; al-
though it appears that through its reversible binding to
tubulin, CA4P causes distortion and detachment of imma-
ture proliferating endothelial cells in abnormal vasculature
(mature endothelial cell shape is maintained by the second-
ary scaffolding protein actin). Because of its reversible
effects and the short half-life of about 10-27 min, as
demonstrated in animal studies, CA4P does not display the
side effects typical of tubulin binding inhibitors [1]. Al-
though it is a vascular targeted agent, its specific mechan-
ism of action and side effect profile differ from those of
vascular endothelial growth factor (VEGF) inhibitors [2].
CA4P has been shown to disrupt tumor neovasculature
and decrease tumor blood flow in both animals and
humans [3]. Multiple human studies have demonstrated
significant decrease in tumor blood flow within a few
hours of CA4P administration, whether examined with dy-
namic contrast enhanced (DCE), MRI, PET scan or perfu-
sion CT scan. The safety profile of CA4P in oncology
patients suggests that adverse effects are generally mild to
moderate and mostly occur in the few hours following an
infusion. Consistent with its vascular activity, the most
typical adverse effects in descending order are nausea,
headache, tumor pain, fatigue, vomiting, sinus tachycardia
and bradycardia, paresthesia, diarrhea, sweating, and tran-
sient hypertension and QTc prolongation [4].
CA4P was reported to decrease neovascularization in
mice with laser-induced disruption of Bruch’s mem-
brane, in VEGF overexpressing mice, and in a model of
retinopathy of prematurity (ROP) induced by excessive
oxygen [5,6]. In the ROP model, CA4P demonstrated
specificity for abnormal vasculature with sparing of nor-
mal angiogenesis required to support growth of the
developing eye. The dose of CA4P required in the laser
burn model was approximately 30-fold higher than that
required in the other two models, suggesting greater po-
tency on abnormal vascular structures in contrast to
normal wound healing [6].
These preclinical observations along with the apparent
tolerability of systemic CA4P in oncology patients [7-10]
provided the rationale for the pilot study of intravenous
CA4P in patients with neovascular AMD. The index
study is the first clinical trial of CA4P in patients with
an ophthalmic disorder, and is the first trial of systemic
CA4P in a population of patients without malignancy.
Therefore, the study may contribute unique safety and
biological activity data to the VDA literature.
Methods
Selection criteria
A prospective, open-label, dose-escalation phase 1 study
was conducted to assess the safety, tolerability, and poten-
tial efficacy of CA4P in patients with choroidal neovascu-
larization (CNV) secondary to AMD. The clinical trial was
approved by the Johns Hopkins Medicine Institutional Re-
view Board (IRB). Prior to determination of eligibility for
enrollment, patients provided informed written consent to
participate in the Study and to allow the information
about them such as their eye, gender, and age (but not
their names and other specific identifiable information) to
be published in scientific literature so that others can be
educated and learn from the trial.
Fluorescein angiography (FA) was employed to docu-
ment presence of active subfoveal CNV. Patients with
conditions that might contribute to CNV, such as patho-
logic myopia, histoplasmosis, and others were excluded.
The CNV lesion size was limited to ≤12 Macular Photo-
coagulation Study (MPS) disc areas, of which at least 50%
had to be active CNV. Subretinal hemorrhage was limited
to <50% of total lesion size and scarring or atrophy to
<25% of lesion size.
All major types of CNV were eligible. However, in
patients with minimally classic or purely occult CNV,
there has to be a documented evidence of two or more
lines of vision loss during the previous 12 weeks. Eyes
with best corrected visual acuity (BCVA) equivalent to
20/40 or worse, as measured by ETDRS charts, were eli-
gible provided BCVA in the fellow eye is equivalent to
20/800 or better. When both eyes were eligible, the eye
with better vision was selected.
Patients with any therapy for neovascular AMD within
12 weeks of screening or with prior subfoveal thermal laser
therapy were excluded. There were specific exclusions
for history of hemorrhagic or bleeding disorders and for
cardiac disease, including angina, myocardial infarction,
congestive heart failure or diagnostic tests showing an
ejection fraction less than 50%, atrial fibrillation, clinically
significant arrhythmias, and syncope. Conditions or medi-
cations associated with QTc prolongation were excluded.
A normal 12-lead electrocardiogram (ECG) showing a
QTc < 440 ms was required within 4 weeks prior to enroll-
ment. Patients were also required to have a normal cardiac
stress test of any type within 2 months prior to study
entry. Laboratory tests obtained prior to enrollment were
required to demonstrate adequate bone marrow, hepatic
and renal functions, and normal blood coagulation profile.
Uncontrolled hypertension (defined as blood pressure con-
sistently greater than 150/100 mmHg irrespective of medi-
cation) or uncontrolled hypokalemia unresponsive to
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supplementation and/or hypomagnesaemia were exclusion
criteria.
Treatment plan and study design
Patients received CA4P (OxiGene Inc., South San
Francisco, CA) at a dose of 27 or 36 mg/m2 as a 10-
minute intravenous infusion weekly for 4 weeks. Vital
signs were obtained every 15 minutes for two hours and
then hourly for five hours after infusion. ECGs were col-
lected hourly for five hours after completion of the infu-
sion. Adverse events (AEs) were collected and graded
using The NCI Common Terminology Criteria for Ad-
verse Events (CTCAE) v 3.0. Subjects were reassessed
and had to continue to meet inclusion/exclusion criteria
for hematologic, hepatic, and renal functions prior to
each scheduled dose. No further CA4P would be admi-
nistered to any subjects who experienced AEs of Grade-
2 or greater: ventricular arrhythmia, second or third
degree AV block, severe sinus bradycardia less than
45 bpm or tachycardia >120 bpm not due to other
causes (e.g. fever), persistent supraventricular arrhythmia
[e.g. atrial fibrillation, flutter, atrioventricular nodal
tachycardia (AVNRT)] lasting more than 24 hours,
ventricular tachycardia defined as >9 beats in a row,
or any length of torsades de pointes (polymorphic
ventricular tachycardia with long QTc), or unexplained
recurrent syncope), QTc prolongation in which the
interval exceeds 500 msec on any two consecutive ECGs,
Grade-2 or greater myocardial infarction, or ocular toxi-
cities deemed by the investigator not acceptable for the
patients to receive further treatments. A cardiac electro-
physiologist (JKD) reviewed the ECGs and made recom-
mendations pertaining to the conduct of the study. In
addition, an anesthesiologist participated in taking care
for the patients during the study, including the manage-
ment of hypertension.
The study was designed as a single escalating dose
with cohorts of five subjects. Escalation to the next co-
hort was based on the presence of no more than one
subject with a dose limiting toxicity (DLT). DLTs were
defined as specific events that are considered to be prob-
ably or definitely related to CA4P. Major DLTs included
QTc interval ≥ 500 msec (based on measurements pro-
vided by the core laboratory for ECG analysis), Grade-2
or greater ventricular arrhythmia, unexplained syncope,
Grade-3 or greater toxicity, delayed recovery postponing
re-treatment by >14 days, and ocular toxicity such as
keratopathy, uveitis, optic neuropathy, and retinopathy,
at the discretion of the investigator.
Prior to each treatment, patients had ocular and phys-
ical examinations, ECG, complete blood count, and
serum chemistry determinations. These safety tests were
also performed 1 and 2 months following the last ad-
ministration of CA4P. Ocular examination included slit-
lamp biomicroscopy, indirect ophthalmoscopy, intraocu-
lar pressure (IOP) measurements, and BCVA. Assess-
ment of CNV was performed using FA and OCT at
screening, 1 hour after the first infusion, and immedi-
ately prior to the second, third, and fourth infusions,
and at 4-week and 8-week visits. BCVA was assessed at
all the visits prior to infusion.
Statistical methods
Descriptive statistical summaries were performed for
safety and efficacy parameters. There were no predictive
statistical designs used in this pilot study.
Results
Patient characteristics
Between August 2003 and May 2005, 15 patients with
AMD were screened at a single center, the Wilmer Eye
Institute at the Johns Hopkins University. Seven subjects
were not eligible; eight subjects were enrolled; five sub-
jects received 27 mg/m2 and three subjects received
36 mg/m2. The age of the enrolled patients ranged from
57 to 84 years (Table 1). BCVA in the study eyes ranged
from 25 to 73 letters and in the fellow eyes ranged from
zero to 80 letters. At baseline, all patients had active
subfoveal CNV: occult in 6 patients and minimally clas-
sic in two. In the fellow eyes, 5 patients had active CNV
at baseline, one patient had history of CNV resolved
with disciform scarring and light-perception vision, and
two patients had no history of CNV. None of our
patients was naïve to treatment at baseline with all of
them receiving at least 2 sessions of photodynamic ther-
apy (PDT) prior to the study (Table 1).
Systemic safety
The majority of the adverse events were encountered dur-
ing infusion and within the following 5 hours. The most
common AEs were transient elevated blood pressure
(46.7%), transient QTc prolongation (23.3%), elevated
temperature (13.3%), and headache (10%), followed by
nausea, and eye injection (6.7% each). Other noted AEs
included T-wave inversion, tachycardia, premature ven-
tricular contractions, and chest pain. All AEs resolved
before dismissal of the patient no later than 5 hours post-
infusion. There were no AEs that were considered serious
or severe (Grade-3 or 4) and none resulted in discontinu-
ation of treatment. One patient did not receive all four
administrations of CA4P secondary to non-specific gastro-
intestinal symptoms that were not considered grade-3 or 4.
Systolic and diastolic blood pressure changes following
the first infusion of CA4P in each subject are shown in
Figure 1. Prior to treatment, one subject was normoten-
sive (systolic ≤120 mmHg), three were borderline hyper-
tensive (systolic >120 and ≤140 mmHg), and four were
hypertensive. The changes in the mean systolic blood
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pressure were similar following each of the four infu-
sions (Table 2). The average systolic blood pressure at
baseline was 145 mmHg and the average diastolic pres-
sure was 74 mmHg. Six patients (75%) showed either
worsening of the pre-existing systolic blood pressure (an
increase of >20 mmHg) or development of hypertension
(elevation of systolic blood pressure >140mgHg). The
elevation in systolic blood pressure was transient and
resolved spontaneously within the post-infusion period.
Diastolic blood pressure did not show any significant
change in any patient either after the infusion or during
the course of the study. The average systolic blood pres-
sure at the end of the study was 142 mmHg and the
average diastolic blood pressure was 72 mmHg.
One subject had a baseline pressure of 156/82 mmHg
despite prescriptions of lisinopril, atenolol and hydro-
chlorothiazide. Following the first administration of
CA4P, her blood pressure climbed to 216/102 mmHg
45 minutes post infusion and returned to baseline level
two hours post-infusion. Prior to the planned second
treatment, blood pressure was 176/84 mmHg, so CA4P
was withheld and lisinopril dose was increased. Prior to
next infusion, blood pressure was 164/75 mmHg and
peaked to 226/102 mmHg one hour post-treatment. The
subject complained of chest heaviness that was not
accompanied by ECG changes. Two doses of nitroglycer-
ine were administered without relief; however, an oral
antacid relieved the symptoms. The absence of ECG
changes and the resolution of heartburn with antacid/
belching suggested the symptoms to be of gastro-
intestinal origin. Due to the adverse experiences, the
patient did not receive any further administration of
CA4P.
Baseline QTc was normal for all patients (median
409 ms, range 396-426 ms). QTc increased in all patients
after infusion of CA4P, with a peak QTc significantly
higher than baseline (median 438 ms, range 418–474 ms,
p < 0.05). The changes in QTc interval following first infu-
sion of CA4P are shown in Figure 2. The time-to-peak
QTc was a median of 2 hours post-infusion (range 1–
5 hours). Two female patients had grade-1 prolongation
of QTc ≥450 ms (3/4 infusions; patients 3 and 5), and
one had a grade-2 complication of QTc peak ≥ 470 ms
(1/4 infusions: patient 5). The relative increase in QTc did
not correlate with baseline QTc (linear regression r = 0.15,
p = 0.49). Mean changes in QTc are summarized in
Table 2.
Ocular safety
Two of the eight patients experienced unilateral con-
junctival injection during one of their treatments; an-
other patient reported flashes and floaters in one eye.
Both observations were transient and resolved without
sequelae. Both observations were judged to be related to
the study drug but were not serious adverse events.
Since no DLTs were observed, a maximal tolerated dose
(MTD) was not defined in this study.
Ocular efficacy
Study eyes
The mean foveal thickness of the central 1 mm of the
retina (FTH) in the study eyes was 346 μm at baseline
Table 1 Demographics of the study subjects who were treated with intravenous combretastatin A-4 phosphate and
characteristics of study and fellow eyes at baseline
Patient Age Gender Race Previous
treatment
CNV SE CNV FE BCVA FTH
SE FE SE FE
1 81 F White PDT × 3 Subfoveal occult Disciform Scar* 60 25 187 127
2 82 F Hispanic PDT × 2 Subfoveal occult Subfoveal occult
disciform scar*
73 4 204 573
3 84 F White PDT × 2 Subfoveal occult No CNV 64 80 404 183
4 57 M White PDT × 3 Subfoveal
minimally classic
Extrafoveal active
occult foveal disciform
scar *
67 73 346 236
5 64 F White PDT × 4 Subfoveal occult
with disciform scar
Disciform scar 30 PL 519 x
6 70 M White PDT × 2 Subfoveal
minimally
Subfoveal occult* 72 47 366 256
7 75 F White PDT × 2 Subfoveal occult No CNV 25 72 292 238
8 79 F White PDT × 3 Subfoveal occult Subfoveal occult* 64 48 450 393
Mean
(±SD)
74
(±9.6)
56.9 (18.7±) 49.9 (±27.9) 346.0 (±115.2) 286.6(±150.2)
The asterisks indicate the fellow eyes that had active CNV at baseline. CNV = Choroidal neovascular membrane; SE = Study Eye; FE = Fellow Eye, BCVA = Best
corrected visual acuity; FTH = central foveal thickness; PDT = photodynamic therapy; M = Male; F = Female; SD = Standard deviation.
Ibrahim et al. BMC Pharmacology and Toxicology 2013, 14:7 Page 4 of 10
http://www.biomedcentral.com/bmcpharmacoltoxicol/2050-6511/14/1/7
(Figure 3 top), with an excess FTH of 134 μm [normal
FTH= 212 μm as measured by OCT2 (Carl Zeiss Meditec,
Inc.)]. After the 4th infusion (end of treatment period), the
mean FTH showed a 32.37 μm reduction (313.63 μm),
representing 24.15% decrease in excess FTH. The change
in FTH was not statistically significant when assessed
using Wilcoxon signed rank test (P = 0.674). FTH contin-
ued however to decrease during the follow-up period with
thickness values of 294 μm and 287.38 μm, one and two
months after the last treatment, respectively. The total re-
duction in FTH at the end of follow-up period (8 weeks
after last infusion) represented 43.75% of the excess FTH
at baseline (p =0.161).
Despite the reduction in the central foveal thickness,
BCVA remained mainly unchanged throughout the
study. At baseline, mean BCVA in the study eyes was
57.75 letters (20/80-20/63). During the treatment period,
the maximum mean BCVA was 57.63 letters, reached at
Figure 1 Changes in systolic (top) and diastolic (bottom) blood pressure in the study subjects following the first infusion of
combretastatin A-4 phosphate.
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week 3 (before 3rd infusion) and week 4 (the end of treat-
ment period, before 4th infusion, i.e. the patients only
received 3 treatments at the time of the VA measure-
ments), and the minimum was 55.5 letters reached at
week 2 (before 2nd infusion). During follow-up period,
the mean BCVA was 55.5 letters at week 8 (p =0.128)
and 56.13 (20/80) letters at week 12 (p = 0.398), losing
1.63 letters when compared to the baseline visual acuity.
Fluorescein angiography images of the study eyes at
baseline showed that six study eyes had macular leakage
of 1 to 2 MPS disc areas. Two eyes had large CNV lesions
with leakage of 10 to 12 MPS disc areas. Of these two
eyes, one eye had extensive hemorrhage and the other eye
showed disciform scarring. At the end of the treatment
period (after 4th infusion), the FA images from five
patients did not show any changes in the size of leakage
area. Of the other three eyes, one eye showed mild reduc-
tion and two eyes showed mild increase in leakage.
Fellow eyes
Five of the fellow eyes had neovascular AMD with mean
FTH of 318.67 μm at baseline (an excess FTH of
106.67 μm) (Figure 3 bottom). At the end of the treat-
ment period (after 4th infusion), the mean FTH showed
a 31.92 μm reduction (286.75 μm) representing 30% of
excess FTH at baseline. The fellow eyes maintained the
reduced FTH during the follow-up period with FTH of
284.5 μm and 287 μm, one and two months after the last
infusion of CA4P, respectively. The change in foveal
thickness was not statistically significant when assessed
using non-parametric testing with Wilcoxon signed rank
test with p >0.5 at every visit.
Table 2 Changes in the mean systolic blood pressure and QTc interval following each infusion of combretastatin A-4
phosphate (SE = Standard error)
1st infusion 2nd infusion 3rd infusion 4th infusion
mmHg (SE) QTc in μm (SE) mmHg (SE) QTc in μm (SE) mmHg (SE) QTc in μm (SE) mmHg (SE) QTc in μm (SE)
Prior to Infusion 145 (4.8) 411 (3.51) 131 (3.38) 406 (3.25) 136 (4.78) 412 (3.58) 132 (7.11) 415 (6.14)
Hour 1 164 (7.9) 419 (4.41) 165 (5) 405 (4.75) 163 (9.48) 416 (3.44) 154 (4.84) 417 (4.82)
Hour 2 149 (6.66) 430 (10.12) 148 (5.53) 427 (8.09) 148 (5.32) 428 (6.62) 139 (6.56) 425 (8.75)
Hour 3 143 (6.31) 424 (7.23) 141 (2.95) 422 (4.78) 139 (5.33) 428 (6.01) 136 (7.8) 424 (7.47)
Hour 4 144 (7.6) 426 (4.93) 137 (4.5) 426 (4.78) 131 (5.75) 424 (5.09) 128 (6.63) 423 (7.35)
Hour 5 148 (9.7) 423 (7.55) 137 (5.08) 429 (12.83) 142 (3.62) 423 (6.61) 138 (5.72) 421 (7.65)
Figure 2 Changes in the QTc interval in the study subjects following the first infusion of combretastatin A-4 phosphate.
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At baseline, the mean BCVA in the fellow eyes was 39.2
ETDRS letters (20/160). At the end of the treatment
period, there was a gain of 4.8 ETDRS letters (44 letters =
20/125). The fellow eyes maintained the improvement
in BCVA. At the end of the follow-up period (8 weeks
after last infusion), BCVA remained at 43.4 ETDRS letters
(20/125). However, the improvement of BCVA was not
statistically significant following third infusion (p = 0.39)
and at the end of the study (p = 0.38).
Discussion
Targeting the growth factors and signaling pathways
involved in endothelial cell proliferation has led to the
development and approval of the antiangiogenic therap-
ies, pegaptanib and ranibizumab in neovascular AMD.
The primary goal of these agents is to suppress the
growth of new vessels underneath the retina. CA4P
represents a lead compound in a separate group of
agents known as VDAs that, unlike anti-VEGFs, are
Figure 3 Mean changes in visual acuity and central retinal thickness during the study period in the study eyes (top) and the fellow
eyes (bottom).
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designed to selectively and rapidly compromise abnor-
mal neovasculature. CA4P has been administered to
patients with refractory solid tumors in multiple Phase
1, 2 and 3 trials [4,7,9,10].
Our study represents the first study of CA4P for an oph-
thalmic disease in humans. Clinical experience with CA4P
consists of 18 completed and ongoing clinical trials in on-
cology and ophthalmology, together comprising more
than 350 patients [4]. CA4P is currently being studied in
patients with non-small cell lung cancer (NSCLC), ana-
plastic thyroid cancer (ATC) and platinum-resistant ovar-
ian cancer. However, CA4P has not been investigated in
patients without systemic malignancies until this study. As
a VDA, it is expected that CA4P will have some vascular
activities and that potential cardiovascular adverse events
could be seen. In general, cardiovascular events have been
observed at lesser frequency in doses of CA4P < 50 mg/
m2. In our study, negative cardiac stress was an inclusion
criterion; however, current studies with CA4P in oncology
and ophthalmology do not require such testing as part of
the screening procedures.
The class side effects of VDA encountered in oncology
studies [7,9,10] were observed in our study population
as well. However, CA4P was tolerated in our study with-
out experiencing severe adverse effects of Grade-3 or 4
(CTCAE v.3.0). The most commonly encountered adverse
event in our study was transient hypertension. Tubulin
depolymerization is believed to be responsible of this tran-
sient elevation of blood pressure. Depolymerization of
endothelial microtubules makes vessels more sensitive to
vasoconstriction and, consequently, hypertension [4]. Ele-
vation of blood pressure is of particular concern in our
study population giving the susceptibility and high preva-
lence of hypertension in the age group of neovascular
AMD. The majority of our study patients had either a pre-
existing or a borderline hypertension, which, along with
other factors such as the presence of higher risk factors of
cardiovascular disease in our study’s age group, may be re-
sponsible for the higher incidence of post-infusion hyper-
tension in our study (75%) when compared with the
reported rates in oncology (30%) [11]. In support of our
explanation, the SANA study [12] have demonstrated that
when bevacizumab was administered intravenously in
patients with neovascular AMD it resulted in an incidence
of hypertension (78%), which is comparable to our study
results. The BEAT-AMD Study has reported a mean
elevation of systolic blood pressure from 140 mmHg
to 150 mmHg in patients who received bevacizumab
intravenously [13]. In another study, Geitzenauer et al.
reported comparable (to ours) elevation in blood pressure
following intravenous administration of bevacizumab in
patients with neovascular AMD, which has peaked in the
second day post infusion. In all previous studies that eval-
uated intravenous bevacizumab, the investigators have
concluded that the elevated blood pressure is insignificant
[14]. However, despite having generally comparable
results, our study cannot be directly compared with the
previous studies due to the different methodologies
employed and different patient characteristics. For ex-
ample, it is not known from the BEAT-AMD Study,
whether blood pressure has or has not elevated in the im-
mediate post-infusion hours, which was when we noticed
the transient hypertension in our patients [13]. In
addition, while our study has allowed patients with high
blood pressure to participate, Geitzenauer et al., have
excluded patients with blood pressure >140/90 mmHg
and patients taking more than one drug to control their
blood pressure; they also did not allow bevacizumab infu-
sion if pretreatment blood pressure is >140/90 mmHg
[14]. Therefore, our results should be taken within their
own context and any comparison with previous studies
that utilized other intravenous agents should be inter-
preted with caution.
Angiotensin converting enzyme (ACE) inhibitors were
used to manage the elevated blood pressure in our study.
However, experiences from more recent studies suggest
that management guidelines using nitrates and calcium
channel blockers can result in a decrease in cardiovascu-
lar toxicity [4,15]. Giving the short-lived duration of ele-
vated pressure, which can be explained by the short
plasma half-life of CA4P, the control of hypertension
may only be required for few hours following the infu-
sion. Routine prophylaxis with a calcium channel
blocker could also become part of the treatment in high-
risk patients [4].
Similar to the elevation in blood pressure, the changes
in QTc were generally mild and confined to the post-
infusion period. QTc could not be predicted from base-
line values. Current clinical trials, in both oncology and
ophthalmology, implement guidelines with magnesium
and potassium supplementation to decrease or prevent
episodes of QTc prolongation.
Consistent with previous studies [8,16,17], intravenous
CA4P did not show any cytotoxic side effects, and also
did not demonstrate adverse effects previously reported
with intravenous anti-VEGF agents, such as proteinuria,
hemorrhage or thrombosis; however, our pilot study
sample was too small to uncover all potential AEs asso-
ciated with CA4P.
There were no serious ocular AEs associated with
CA4P therapy. Such result should be interpreted with
caution giving the small sample size and the non-
randomized open label design of this pilot study.
The observations in our study further extend the
reported effects of CA4P in animal models of ocular dis-
ease [5,6] with suggestive evidence of biological activity
in human subjects with neovascular AMD. Such effect is
evidenced by the reduction of the excess foveal thickness
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in the study eyes by 24.15% and 43.75% at the end of the
treatment and follow-up periods, respectively. A similar
sustainable reduction was also observed at the end of
the treatment period in the fellow eyes that had CNV.
The results need to be taken with caution giving the lim-
itations of the OCT technology utilized in our study.
Other studies utilizing the newly emergent spectral do-
main technology may shed different light on the ana-
tomical outcome of CA4P therapy in neovascular AMD.
The fact that the FTH reduction in our study is much
less pronounced than with anti-VEGF as demonstrated
in some studies [12,14] can be explained in part by the
advanced disease of our study sample. It is also possible
that a vascular disrupting agent does not have as signifi-
cant effect in reducing retinal edema as an anti-VEGF
agent.
At the functional level, BCVA remained stable in the
study eye for the 12-week duration of the study, which
may be attributed to either the nature of the disease or
the bioactivity of CA4P. As the number of study subjects
was small, it would not be appropriate to generate con-
clusions regarding the bioactivity of the drug. However,
the visual gain in the fellow eye and the stability of
BCVA in the study eye, in addition to the observed
reduction of the retinal thickness in both study and fel-
low eyes, may warrant further exploration of the poten-
tial beneficial effects of CA4P in eyes with neovascular
AMD. Significant visual gain has been reported in
patients who received intravenous bevacizumab [12,14].
In the SANA study patients gained a median of 8 letters
over 12 weeks [12]. Nevertheless, all studies were non-
controlled, non-randomized, open-labeled, and small
sampled; hence, no directed comparison can be accur-
ately drawn between both studies. In the only controlled
study, the BEAT-AMD Study did not demonstrate
significant change in BCVA in patients with neovascular
AMD when treated with intravenous bevacizumab,
which seems consistent with our results [13]. All
patients enrolled in our study presented at baseline with
active disease despite at least two sessions of PDT, which
perhaps indicate a level of severity that may not be
present in many of the anti-VEGF studies.
No maximal tolerated dose (MTD) was determined in
this study. The dose levels employed, 27 to 36 mg/m2, are
below the MTD (approximately 60 mg/m2) that was inde-
pendently determined in three separate oncology studies
[9,10]. The dose level of 27 mg/m2 was approximately the
threshold dose for inhibition of blood flow in oncology
studies. Investigators concluded that significant impact on
tumor blood flow was observed in a higher proportion of
patients when dose levels of 40 to 60 mg/m2 were admi-
nistered [4,7,9,18]. Further assessment of the dose depend-
ency of CA4P for CNV might be of interest due to the
potential for greater biological effect with higher doses,
provided no additional or more severe adverse events are
noted.
Compared with the current intraocular treatment options
that are available for patients with neovascular AMD,
agents administered intravenously, especially those with
potential systemic effects, are admittedly less appealing to
patients and ophthalmologists. However, the novelty of
mechanisms though which CA4P exerts its biological activ-
ity may add to the expanding arsenal of therapeutic options
available today for patients with neovascular AMD. Fur-
thermore, recent studies in rabbits and primates have sug-
gested that topical administration of CA4P allows sufficient
penetration of the drug to the choroid [19]; hence, localized
ocular therapy with CA4P may be feasible and available in
the future. In addition, further study of systemically admi-
nistered CA4P in AMD may be warranted, especially if the
associated side effects are known and can be controlled
with proper therapy and monitoring.
Although CA4P is an anti-vascular agent, its mechan-
ism of action and side effect profile differs from that of
anti-angiogenic VEGF inhibitors. Synergetic inhibitory
effects of CA4P and bevacizumab on blood flow have
been demonstrated in recent studies in both xenograft
models and in patients with refractory solid tumors.
CA4P may, therefore, have potential role in the manage-
ment of neovascular AMD and other retinal vascular
diseases, either as monotherapy or in combination with
anti-VEGF treatments, especially if topical or intravitreal
or other local formulation/s are developed.
Conclusion
The safety profile of intravenous CA4P was consistent
with that reported in oncology patients and with the class
effects of vascular disruptive agents. There are evidences
to suggest efficacy of CA4P in neovascular AMD. How-
ever, the level of systemic safety and efficacy indicates that
systemic CA4P may not be suitable as an alternative
monotherapy for neovascular AMD, especially when com-
pared to the overall safe and very effective intravitreal
anti-VEGF therapy today. There might be a role for CA4P
as an adjunctive therapy, to be used in combination ap-
proach, when delivered intravitreally/topically. Further
studies of CA4P in AMD and other ophthalmic disorders
are indicated to investigate the potential role of vascular
disrupting agents in the management of angiogenic retinal
vascular diseases.
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